Anti-CD70, Recombinant [TAN 1-7]
Invented at University of Southampton
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153278 |
| Applications | ELISA FACS IF Fn |
| Antigen/Gene or Protein Targets | CD70 |
| Synonyms | CD70 Molecule; Tumor Necrosis Factor Ligand Superfamily Member 7; CD27 Ligand; CD27LG; TNFSF7; CD27L; Tumor Necrosis Factor Ligand 8A; Surface Antigen CD70; Ki-24 Antigen; CD70 Antigen; TNLG8A |
| Reactivity | Mouse |
| Relevance |
Recombinant monoclonal antibody directed against CD70 cytokine, capable of blocking the CD70-CD27 interaction involved in B and T cell activation. Background and Research Application CD70 is a cytokine that belongs to the tumour necrosis factor (TNF) ligand family. This cytokine is a ligand for TNFRSF27/CD27. It is a surface antigen on activated, but not on resting, T and B lymphocytes and dendritic cells. It induces proliferation of co-stimulated T cells, enhances the generation of cytolytic T cells, and contributes to T cell activation. This cytokine is also reported to play a role in regulating B cell activation, cytotoxic function of natural killer cells, and immunoglobulin synthesis. CD70 expression is induced upon activation of DCs, indicating that the CD70-CD27 interaction could take place during the activation of naive T cells by DCs. A recombinant version of anti-CD70, a non-depleting antibody which blocks the CD70-CD27 interaction. CD70 expression is thought to play a role in autoimmune disease regulation, and treatment of autoimmune diseases such as rheumatoid arthritis. |
| Host | Rat |
| Immunogen | Recombinant mouse CD70 (extracellular domain, aa residues 41-195) |
| Subclass | IgG2a |
| Formulation | PBS |
| Concentration | 1mgml-1 |
| Positive Control | Activated dendritic cells |
| Research Area | Immunology |
| Immunogen UniProt ID | O55237 |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest This antibody is a non-depleting mAb that blocks the CD70-CD27 interaction. Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. Suggested Dilutions: 1-10mg/ml Five variants available: - Anti-CD70 [TAN 1-7], Rat IgG2a, Kappa - Anti-CD70 [TAN 1-7], Mouse IgG2a, Kappa - Anti-CD70 [TAN 1-7], Mouse IgG2a, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors - Anti-CD70 [TAN 1-7], Mouse IgG1-D265A, Fc Silenced, Kappa - Anti-CD70 [TAN 1-7], Rabbit IgG, Kappa Concentration 1mg/ml as standard |
References: 1 entry
Original hybridoma first published in: Rowley et al. 2004. J Immunol. 172(10):6039-46. PMID: 15128787.
Add a reference
References: 1 entry
Original hybridoma first published in: Rowley et al. 2004. J Immunol. 172(10):6039-46. PMID: 15128787.
Add a reference
